Top 10 MedTech Startups in Australia 2025

Australia is rapidly becoming a global hub for medical technology innovation. In 2025, the country’s medtech sector stands at the intersection of science, engineering and healthcare, offering cutting-edge solutions that are transforming patient outcomes both locally and internationally, too.

From AI-assisted diagnostics to breakthrough surgical tools and remote monitoring systems, Australian startups and established firms alike are redefining how healthcare is delivered.

Whether it’s about tackling chronic disease, enhancing surgical precision or speeding up clinical trials, these companies exemplify the best of Australian innovation in action, with medical professionals and other experts making incredible strides in improving medicine for people all over the world.

 

MedTech in Australia: Past, Present and Future

 

Over the past decade, Australia’s medtech industry has evolved from a niche sector into a powerhouse of innovation. Driven by strong research institutions, public-private partnerships and government support, the country has seen a surge in startups tackling unmet medical needs.

Indeed, advances in digital health, AI, biotechnology and remote care have gained traction, especially in the wake of the global pandemic. As healthcare moves towards personalised, preventative and connected models, Australian medtech is poised to play a global role.

In the coming decade, the sector is expected to grow significantly, fuelled by increasing demand for smart diagnostics, wearable health tech and minimally invasive therapies, placing Australia firmly on the world stage as a leader in health innovation.

 

The 10 Top MedTech Startups in Australia 2025

 

Here are the top 10 medtech startup in Australia in 2025.

 

OncoRes Medical

 

Founded in 2016 in Perth, Western Australia, OncoRes Medical is transforming cancer surgery with its real-time intraoperative imaging technology. Its handheld probe, paired with AI, helps surgeons detect residual cancer cells during breast-conserving surgery, increasing precision and reducing reoperations.

The system offers real-time feedback, improving both clinical outcomes and patient recovery. Backed by the Australian Government’s BioMedTech Horizons programme, OncoRes has won multiple innovation awards. By combining imaging, machine learning and surgical integration, the company stands out as a leading force in Australia’s medtech scene and shows how innovation can directly improve surgical care.

 

Harrison.ai

 

Launched in 2018 in Sydney, Harrison.ai focuses on building clinical AI tools in partnership with healthcare providers. The company is best known for co-creating Annalise.ai, a radiology diagnostics platform, and Franklin.ai for pathology workflows.

Harrison.ai has secured over AUD $100 million in funding and works with partners like I-MED and Sonic Healthcare to bring AI into hospitals. By combining clinician expertise with powerful machine learning, Harrison.ai delivers scalable tools that improve diagnostic speed and accuracy. The company’s platform-based model is helping reimagine medical diagnostics, making it a standout name in the AI-driven healthtech revolution.

 

 

Arkwright Technologies

 

Founded in 2020 in Sydney, Arkwright Technologies develops smart remote monitoring tools using biosensors and cloud-connected devices. The company’s solutions are designed for high-risk patients, enabling early detection of health issues in aged care, post-operative and home settings.

Its flagship product provides clinicians with continuous vital sign monitoring and AI-driven alerts. Arkwright Technologies prioritises user-friendly designs, making it easier for healthcare staff and carers to adopt. With a focus on scalable, preventative healthcare, the company is playing a vital role in the shift from reactive to proactive medicine within Australia’s expanding digital health ecosystem.

 

Q-Sera

 

Q-Sera was established in 2011 in Brisbane, spun out from the University of Queensland. The company is developing next-generation blood collection tubes that use a venom-derived protein to rapidly clot blood, significantly speeding up lab diagnostics.

This innovation is especially valuable in emergency departments where time is critical. Q-Sera’s technology ensures faster and more consistent serum separation, improving workflow efficiency for pathology labs.

The company has secured partnerships with major global diagnostics firms and has attracted international investment. Q-Sera is a compelling example of how Australian biotech is solving practical clinical challenges through clever science.

 

NanoSonics

 

Founded in 2001 in Sydney, Nanosonics is a global leader in infection prevention, best known for its Trophon device, which disinfects ultrasound probes using hydrogen peroxide mist. The system is widely used in hospitals across Europe, North America and Asia.

Nanosonics addresses critical hospital-acquired infection risks while offering sustainable and automated solutions. The company is listed on the ASX and continues to invest in R&D to expand its infection control portfolio. With a growing global footprint and a commitment to safer healthcare environments, Nanosonics remains one of Australia’s most successful and enduring medtech pioneers.

 

PainChek

 

PainChek was established in 2016 in Sydney and has created the world’s first clinically validated AI app to assess pain in people unable to self-report, such as those with dementia. Using facial recognition and micro-expression analysis, the app generates an objective pain score in real-time.

PainChek is already widely used in Australian aged care settings and has expanded into the UK and Singapore. The company’s mission to provide better pain management in vulnerable populations is gaining global traction. PainChek represents a powerful combination of empathy and technology in modern healthcare, tackling a crucial problem with precision and care.

 

Anteris Technologies

 

Founded in 2005 in Brisbane, Anteris Technologies focuses on structural heart innovations, especially its proprietary DurAVR™ transcatheter aortic valve. Designed to mimic the natural function of heart valves, DurAVR™ offers improved durability and haemodynamic performance.

Initially operating as Allied Medical, the company rebranded and pivoted toward cutting-edge cardiovascular solutions. Anteris has received international attention for its 3D single-piece leaflet design, a first in the transcatheter valve market. With promising trial results and strategic global partnerships, Anteris Technologies is establishing itself as a major force in the competitive field of cardiovascular medtech.

 

NAVi MEdTech

 

NAVi MedTech was founded in 2019 in Melbourne, specialising in augmented reality (AR) and 3D visualisation tools for surgery. Their proprietary system helps surgeons plan and execute complex procedures with improved precision by overlaying internal anatomical structures onto real-time imaging.

The technology is currently being used in orthopaedic and neurosurgical applications, with strong interest from teaching hospitals and surgical centres. By enhancing surgical planning and execution, NAVi MedTech reduces risks and improves outcomes. Its innovation in AR-guided procedures positions it at the forefront of Australia’s surgical tech frontier, with potential for global impact.

 

Clinials Global Pty Ltd

 

Founded in 2020 in Melbourne, Clinials Global is streamlining the clinical trial process with its secure digital platform. Designed to improve patient recruitment, data management and compliance, the software helps reduce timelines and improve trial quality. The system supports multilingual interfaces and remote monitoring, making it ideal for decentralised trials and global studies.

Clinials Global works with contract research organisations, sponsors, and hospitals to simplify complex trial operations. With clinical trials increasingly digitised and patient-centric, the company is poised for rapid growth and is a strong player in the digital transformation of life sciences.

 

PredictBGL

Developed by DataSense, a startup based in Melbourne and founded in 2013, PredictBGL is an app designed to help people with diabetes predict and manage blood glucose levels. Using AI algorithms and real-time data from connected devices like CGMs and insulin pumps, it delivers personalised predictions and insulin dose guidance.

PredictBGL is especially popular with parents managing Type 1 diabetes in children, offering peace of mind through timely alerts. With its intuitive design and powerful backend engine, the app empowers users to take control of their condition. PredictBGL is part of a growing trend in predictive, patient-centred care.